RFK Launches His Latest MAHA Project

RFK Jr.’s new push to get Americans off antidepressants is turning a private medical decision into a high-stakes national policy fight.

Quick Take

HHS Secretary Robert F. Kennedy Jr. is advancing a “Make America Healthy Again” effort aimed at reducing antidepressant use, including clinician “de-prescribing” training tied to Medicare.
Kennedy has directed federal health agencies to study whether SSRIs and other psychoactive drugs are linked to mass violence—an idea many psychiatric experts dispute.
Critics warn the campaign could stigmatize treatment and discourage patients from seeking care, while supporters argue it challenges overmedication and pharmaceutical influence.
The practical bottleneck is access: non-drug alternatives like therapy are often unaffordable or unavailable, especially for seniors relying on Medicare.

Kennedy’s MAHA agenda moves from rhetoric to federal action

HHS Secretary Robert F. Kennedy Jr. is using his post in the Trump administration to advance a “Make America Healthy Again” initiative that focuses on reducing antidepressant use, particularly SSRIs. The effort has included public claims about potential harms, as well as concrete policy steps—directing agencies to study possible links between psychoactive drugs and mass violence, and promoting “de-prescribing” through clinician training. The approach reflects MAHA’s emphasis on diet, exercise, and therapy over medication.

Kennedy’s timeline shows a steady escalation. Reports describe him linking a 2025 Minnesota school shooting to SSRIs in media appearances and later pointing to federal studies as the next step. At his January 2026 confirmation hearing, he drew particular attention by comparing SSRI withdrawal to heroin. Whether one sees that as a warning about dependency or a rhetorical overreach, the statement underscores a central question: will HHS use its authority to inform medical practice—or to pressure it?

What the research debate actually shows—and what remains unproven

Psychiatric experts quoted in coverage argue that the evidence does not support a causal link between SSRI use and mass violence. Their core point is straightforward: severe depression or other serious mental illness can correlate with both medication use and dangerous behavior, but correlation is not causation. That distinction matters because federal messaging can reshape patient behavior quickly. As of spring 2026, the government-directed studies referenced in reporting appear to be underway, but definitive results have not been publicly detailed.

History is a warning label here. Coverage points to the post-2004 period, when FDA “black box” warnings about suicidality in youth were followed by a major drop in antidepressant prescribing and, according to studies cited in reporting, an increase in suicides—without a corresponding benefit related to violence. That episode is frequently invoked by critics of Kennedy’s campaign as evidence that broad-brush fear can backfire. Supporters counter that scrutinizing prescribing patterns is legitimate, especially if lifestyle interventions can help.

Medicare “de-prescribing” meets a real-world access wall

Policy details matter more than slogans. A major development highlighted in 2026 reporting is a push for clinician training aimed at helping Medicare patients taper off antidepressants. The idea sounds simple: support patients who want to stop medication and substitute non-pharmacological care where appropriate. The implementation problem is availability. Advocacy coverage argues that therapy access is limited for Medicare beneficiaries, with large shares of providers not accepting Medicare or remaining out-of-network, raising the risk that patients are told to quit pills without receiving a workable alternative.

This is where frustrations on both the right and the left collide. Conservatives skeptical of pharma profits and bureaucratic groupthink may welcome a federal challenge to automatic long-term prescribing. Liberals worried about unequal healthcare access see an underfunded mandate that shifts burden onto patients. In either case, a federal campaign that encourages “less medication” while budgets tighten can look like Washington trying to manage outcomes without paying for the infrastructure—fuel for the broader belief that government often overpromises and underdelivers.

What Americans should watch next: messaging, evidence, and guardrails

The next phase hinges on how Kennedy’s department communicates risk. Studying outcomes is one thing; signaling that antidepressants are a driver of violence is another, especially before studies are complete and publicly vetted. If HHS wants to promote safer tapering, it will need clear guardrails: emphasizing that abrupt discontinuation can be dangerous, that decisions belong with clinicians and patients, and that severe depression carries its own risks. The credibility of MAHA will be tested by whether it prioritizes evidence over headlines.

RFK Jr. Launches His Latest MAHA Project — Getting Americans Off Antidepressants https://t.co/pxMO3Qi9yd #gatewaypundit via @gatewaypundit To think this was all possible following the Obama Biden era… What a world we may have!

— markgoethel (@markgoethel) May 6, 2026

For the public, the most practical takeaway is to separate two debates that often get lumped together. Debate one is cultural and political: distrust of “experts,” resentment of corporate influence, and anger at a system that feels rigged. Debate two is clinical: which patients benefit from SSRIs, which can taper safely, and what supports are necessary. Until federal studies are transparent and access problems are addressed, Americans should expect the antidepressant fight to remain a proxy battle over power, trust, and the limits of government-led health reform.